The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Subscribe To Our Newsletter & Stay Updated
